ADVERTISEMENT

Clinical Summary

Prostate cancer: quality-of-life data support add-on olaparib

Deepa Koli   |   13 September 2022

Takeaway

  • In previously treated patients with metastatic castration-resistant prostate cancer, no significant difference in health-related QoL and pain is reported with olaparib plus abiraterone compared with placebo plus abiraterone.

Why this matters

  • These QoL data will help support informed decision making by patients and clinicians.

Study design

  • A double-blind, randomized, placebo-controlled, phase...

          

November Challenge

Ends in 9h
left
right

Topic Challenges

left
right